Literature DB >> 12194746

Tamoxifen in antiretroviral-associated gynaecomastia.

Stephen Kegg1, Richard Lau.   

Abstract

Gynaecomastia arising in the context of antiretroviral therapy for HIV infection presents a number of challenges in diagnosis and management. We describe a thirty year old gay man with rapidly developing breast enlargement who was successfully treated with the anti-oestrogen tamoxifen.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12194746     DOI： 10.1258/095646202760159756

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN： 0956-4624            Impact factor:   1.359


  5 in total

1.  Differential interactions of antiretroviral agents with LXR, ER and GR nuclear receptors: potential contributing factors to adverse events.

Authors:  J Svärd; F Blanco; D Nevin; D Fayne; F Mulcahy; M Hennessy; J P Spiers
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

2.  The man with bilateral nipple pain.

Authors:  H C Hong; K C Koh
Journal:  Malays Fam Physician       Date:  2013-12-31

3.  Gynaecomastia associated with highly active antiretroviral therapy (HAART).

Authors:  Debra Meerkotter
Journal:  J Radiol Case Rep       Date:  2010-07-01

4.  Efavirenz directly modulates the oestrogen receptor and induces breast cancer cell growth.

Authors:  M J Sikora; J M Rae; M D Johnson; Z Desta
Journal:  HIV Med       Date:  2010-06-28       Impact factor: 3.180

5.  First use of tamoxifen in an HIV patient with encapsulating peritoneal sclerosis.

Authors:  M Mesquita; M P Guillaume; M Dratwa
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.